＜英文論文抜粋＞

①Takarada　T, Fujinaka　R, Shimada　M, Fukuda　M, Yamada　T, Tanaka　  Effect of N-glycosylation on secretion, degradation and lipoprotein distribution of human serum amyloid A4. Biochim Biophys Acta Mol Cell Biol Lipdis. doi: 10.　1016/j.bbalip.2024.1595882026

②Takase H, Tanaka M, Nakamura Y, Morita S, Yamada T, Mukai T. Effects of lipid composition on the structural properties of human serum amyloid A in reconstituted high-density lipoprotein particles. Chem Phys Lipids. 2019;221:8-14

③Okuda Y, Yamada T, Ueda M, Ando Y. First Nationwide Survey of 199 Patients with Amyloid A Amyloidosis in Japan. Intern Med. 2018;57:3351-3355

④Yamada T, Sato J, Kotani K, Tanaka M. Influence of polymorphism on glycosylation of serum amyloid A4 protein. Biochem Res Int 2014:527254, 2014

⑤Yamada T, Okuda Y, Takasugi K, Itoh K, Igari J. Relative serum amyloid A (SAA) values: the influence of SAA1 genotypes and corticosteroid treatment in Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2001;60:124-127

⑥Yamada T, Wada A, Itoh K, Igari J. Serum amyloid A secretion from monocytic leukaemia cell line THP-1 and cultured human peripheral monocytes. Scand J Immunol. 2000;52:7-12

⑦Yamada T, Wada A, Fukuda T, Itoh Y, Itoh K. Changes in apolipoprotein AI and AII concentrations in murine reactive amyloidosis. Scand J Immunol. 1999;50:475-478

⑧Yamada T. Serum amyloid A (SAA): a concise review of biology, assay methods and clinical significance. Clin Chem Lab Med. 1999;37:381-388

⑨Yamada T, Wada A, Itoh Y, Itoh K. Serum amyloid A1 alleles and plasma concentration of serum amyloid A. Amyloid. 1999;6:199-204

⑩Yamada T, Hirano N, Kuroda T, Okuda Y, Itoh Y. Generation and characterization of rat monoclonal antibodies against human serum amyloid A. Scand J Immunol. 1997;46:175-179

⑪Yamada T, Liepnieks JJ, Benson MD, Kluve-Beckerman B. Accelerated amyloid deposition in mice treated with the aspartic protease inhibitor, pepstatin. J Immunol. 1996;157:901-907

⑫Yamada T, Liepnieks JJ, Kluve-Beckerman B, Benson MD. Cathepsin B generates the most common form of amyloid A (76 residues) as a degradation product from serum amyloid A. Scand J Immunol. 1995;41:94-97

⑬Yamada T, Nomata Y, Sugita O, Okada M. A rapid method for measuring serum amyloid A protein by latex agglutination nephelometric immunoassay. Ann Clin Biochem. 1993;30:72-76

⑭Gejyo F, Odani S, Yamada T, Honma N, Saito H, Suzuki M, Arakawa M. Beta2-microglobulin: a new form of amyloid protein associated with chronic hemodialysis. Kidney Int. 1986;30:385-390